0IK fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel biologic drug candidates. Its programs include NGM707 and pembrolizumab for treating metastatic solid tumors, Aldafermin for primary sclerosing cholangitis, and NGM120 for hyperemesis gravidarum. The company was founded by Jin Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
0IK has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company